Retatrutide 60mg UAE: 3D Pen, Research Profile & Product Guide

Retatrutide 60mg UAE is a highly specific search topic for researchers and readers looking for information about Retatrutide, its investigational triple-agonist mechanism, clinical development, and 60mg product formats. The product shown here is labeled RETATRUTIDE 3D 60mg/3ml and is presented in a pre-filled pen format.

Retatrutide, also known by the development code LY3437943, is being investigated as a single molecule capable of activating three metabolic hormone receptors: GIP, GLP-1 and glucagon receptors. Lilly describes Retatrutide as an investigational triple hormone receptor agonist and continues to evaluate it through its clinical development program.

The 60mg/3ml presentation shown in the product image should not be confused with an approved Retatrutide medicine. Packaging claims describe the pictured item; they do not establish regulatory approval, authenticity, clinical equivalence, purity, or authorization.

Retatrutide 60mg UAE Product Overview

The specifications above referring to 60mg/3ml, five doses and export-only status are taken from the packaging visible in the supplied product image and should therefore be understood as label information rather than independent laboratory verification.

What Is Retatrutide?

Retatrutide is an investigational molecule being developed by Eli Lilly. Unlike single-receptor approaches, Retatrutide is designed to activate three different receptors within one molecule:

GIP receptor — involved in metabolic and insulin-related signaling.

GLP-1 receptor — associated with glucose regulation, appetite signaling and metabolic processes.

Glucagon receptor — involved in energy and metabolic regulation.

This three-receptor activity is why Retatrutide is commonly described as a triple agonist. Lilly specifically notes that the informal term “GLP-3” is scientifically inaccurate; triple hormone receptor agonist is the more appropriate description.

Retatrutide 60mg UAE and Current Clinical Research

Interest around Retatrutide 60mg UAE should be separated from the doses and formulations evaluated in controlled clinical trials. A commercial-looking product labeled 60mg does not mean that 60mg represents an approved clinical dose or approved presentation.

Retatrutide has progressed through a substantial Phase 3 research program. ClinicalTrials.gov lists studies evaluating LY3437943 in obesity, overweight, type 2 diabetes and cardiovascular-related populations. For example, TRIUMPH-3 evaluates efficacy and safety in participants with severe obesity and established cardiovascular disease.

In May 2026, Lilly reported topline TRIUMPH-1 results in which participants assigned to the 12mg group had an average body-weight reduction of 28.3% at 80 weeks. These results come from a controlled clinical development program and should not be extrapolated to third-party products labeled “Retatrutide 60mg.”

Additional Phase 3 topline results were announced in July 2026 for TRIUMPH-2 and TRIUMPH-3. Lilly reported average weight reductions of up to 20.8% and 22.6%, respectively, at 80 weeks in the studied populations. The company said it plans a U.S. regulatory submission in Q1 2027.

Retatrutide 3D 60mg/3ml Pen Format

The pictured Retatrutide 3D product uses a pen-style presentation rather than a conventional standalone vial.

Visible packaging states:

• RETATRUTIDE 3D

• 60mg/3ml

• 1 pen contains 5 doses

• For export only

The pen itself is also labeled as a Retatrutide 60mg/3ml product.

These characteristics can be useful for product identification and catalog organization. They should not, however, be interpreted as evidence that the product has been authorized by health regulators.

For SEO purposes, this distinction is especially important when discussing Retatrutide 60mg UAE, because readers may otherwise assume that a product appearing online has the same regulatory status as a licensed medicine.

Retatrutide Research in the UAE

UAE regulatory context is particularly important.

On 6 March 2026, Abu Dhabi's Department of Health issued Circular No. 40/2026 warning healthcare facilities, professionals and the public against unauthorized Retatrutide products. The circular states that Retatrutide remains under clinical development and is not authorized or licensed for use or distribution. It also warns about products of unknown origin being promoted online.

Lilly similarly states that Retatrutide has not yet been approved by any regulatory agency and is not currently available for public use.

Therefore, references to Retatrutide 60mg UAE on this page describe the research compound and pictured product format; they should not be interpreted as indicating UAE regulatory approval.

Why Product Verification Matters

For any product represented as an investigational research compound, the packaging alone cannot establish identity or quality.

Relevant verification may include documentation concerning:

Identity: whether analytical testing corresponds to the compound stated on the label.

Purity: whether appropriate analytical methods have been used to characterize the sample.

Batch traceability: whether lot or batch information can be connected to supporting documentation.

Storage information: whether documented handling conditions are available.

Packaging consistency: whether the outer box, pen labeling and associated documentation correspond with one another.

These considerations become especially important with investigational compounds because they do not have the same authorized commercial supply chain as approved medicines.

Frequently Asked Questions

What is Retatrutide 60mg UAE?

The phrase Retatrutide 60mg UAE refers here to UAE-focused information about a product presented as Retatrutide 3D with a labeled strength of 60mg/3ml. Retatrutide itself remains an investigational compound.

Is Retatrutide a GLP-1 compound?

Retatrutide has GLP-1 receptor activity, but describing it only as a GLP-1 agonist is incomplete. It is designed to activate GIP, GLP-1 and glucagon receptors.

What does the Retatrutide 3D package contain?

The supplied product image states 60mg/3ml and “1 pen contains 5 doses.” These are packaging statements and are not independent verification of the contents.

Is Retatrutide approved in the UAE?

Current official information does not support presenting Retatrutide as an approved UAE medicine. Abu Dhabi DoH specifically issued a warning against unauthorized Retatrutide products in March 2026.

Is Retatrutide still in clinical development?

Yes. Lilly describes Retatrutide as investigational, with an ongoing clinical development program, and says it has not yet received regulatory approval.

Conclusion

Retatrutide 60mg UAE is a useful product-specific topic for understanding the pictured Retatrutide 3D 60mg/3ml pen alongside the broader scientific development of LY3437943. Retatrutide is being investigated as a GIP, GLP-1 and glucagon triple receptor agonist and has progressed through multiple Phase 3 studies.

However, clinical research findings should not be treated as verification of third-party Retatrutide products. The pictured 60mg/3ml pen remains a separately labeled product presentation, while Retatrutide itself remains investigational and unauthorized for routine public use in the UAE.

Disclaimer

This content is provided for research, product-identification and educational purposes only. It is not medical advice, a dosing or administration guide, or evidence of regulatory approval. Product-label information should not be interpreted as independent confirmation of composition, purity, safety or authenticity.